Foal IgG and opsonizing anti-Rhodococcus equi antibodies after immunization of pregnant mares with a protective VapA candidate vaccine.
The aim of this study was to evaluate serum IgG antibody levels and opsonizing activity in foals from pregnant mares immunized with either proteins from an R. equi strain containing virulence-associated protein A (VapA), an immunodominant surface-expressed lipoprotein encoded by a virulence plasmid crucial for virulence in foals, or a whole killed virulent R. equi preparation. Forty-eight pregnant mares were distributed into three groups, i.e. 24 immunized with R. equi VapA protein antigen associated with a water-based nanoparticle adjuvant (Montanide IMS 3012), 8 immunized with whole killed R. equi, and 16 non-immunized as control. Serum IgG and opsonizing capacity were evaluated during pregnancy in mares, and up to day 45 post-delivery in foals in which R. equi infections were recorded in the first 6 months of life. Pregnant mares immunized with virulent R. equi proteins developed higher serum IgG and opsonic activity which were transferred to the foals than either in the whole R. equi immunized or the control group. Four foals developed pneumonia in the control group while none in immunized groups. Results support further evaluation of VapA protein antigen associated with a water-based nanoparticle adjuvant as a candidate vaccine for immunization of pregnant mares resulting in passive antibody-mediated protection of foals.
Cauchard
Julien
J
AFSSA, Laboratoire d'Etudes et de Recherche en Pathologie Equine, IPC, Goustranville, 14430 Dozulé, France. j.cauchard@dozule.afssa.fr
Sevin
Corinne
C
Ballet
Jean-Jacques
JJ
Taouji
Saïd
S
D000193:Actinomycetales Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D000907:Antibodies, Bacterial / Q000097:blood; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology*; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology*; D015153:Blotting, Western / Q000662:veterinary; D005260:Female; D006734:Horse Diseases / Q000276:immunology* / Q000382:microbiology* / Q000517:prevention & control; D006736:Horses; D007112:Immunity, Maternally-Acquired / Q000276:immunology; D007114:Immunization / Q000662:veterinary; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology*; D011247:Pregnancy; D011897:Random Allocation; D016929:Rhodococcus equi / Q000276:immunology* / Q000472:pathogenicity; D014613:Vaccines, Attenuated / Q000276:immunology / Q000592:standards; D015164:Vaccines, Inactivated / Q000276:immunology / Q000592:standards; D037521:Virulence Factors / Q000235:genetics / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D037521:Virulence Factors